Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a … Read more
Polaryx Therapeutics, Inc. Common Stock (PLYX) - Total Liabilities
Latest total liabilities as of September 2025: $682.00K USD
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has total liabilities worth $682.00K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Polaryx Therapeutics, Inc. Common Stock - Total Liabilities Trend (2023–2024)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Polaryx Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Black Sea Property PLC Ordinary Shares
TA:BSP
|
Israel | ILA2.87 Million |
|
UTIMES ORD A (SHH) EQSW Exp:
SHG:688638
|
China | CN¥1.59 Billion |
|
Edri-El
TA:EDRL
|
Israel | ILA53.33 Million |
|
AMG Acquisition Corp
V:AMG-P
|
Canada | CA$10.38K |
|
XTC Lithium Limited
AU:XTC
|
Australia | AU$5.02 Million |
Liability Composition Analysis (2023–2024)
This chart breaks down Polaryx Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Polaryx Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Polaryx Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual total liabilities of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $289.00K | -72.16% |
| 2023-12-31 | $1.04 Million | -- |